Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial - James, ND; Sydes, MR; Clarke, NW (Lancet, 2016)
et al.